Lenvatinib + Pembrolizumab
Treatment for Uterine Cancer
Typical Dosage: Lenvatinib 20mg daily, Pembrolizumab 200mg IV every 3 weeks or 400mg IV every 6 weeks
Effectiveness
65%
Safety Score
35%
Clinical Trials
15
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Lenvatinib 20mg daily, Pembrolizumab 200mg IV every 3 weeks or 400mg IV every 6 weeks
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$325,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$195,000/QALY
QALYs Gained
0.82
Outcome-Based Costs
Cost per Responder
$855,263
Cost per Remission
$6,500,000
Comparison vs Chemotherapy (Doxorubicin or Paclitaxel)
Cost Difference
+$225,000/year
More expensive
QALY Difference
+0.82 QALYs
Better outcomes
Dominance
No dominance
Lenvatinib + Pembrolizumab Outcomes
for Uterine Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+38%
Remission Rate
+5%
Common Side Effects
Hypertension
+70%
Fatigue
+65%
Musculoskeletal pain
+50%
Diarrhea
+45%
Hypothyroidism
+40%
Palmar-plantar erythrodysesthesia
+35%
Proteinuria
+30%
Immune-related adverse events
+20%
Sources:
Active Clinical Trials
8 active trials recruiting for Lenvatinib + Pembrolizumab in Uterine Cancer
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
NCT06266338RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Dallas, United States
Started: Mar 11, 2024
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
NCT04865887RECRUITINGPHASE2
35 participants
INTERVENTIONAL
Washington D.C., United States +3 more
Started: Oct 7, 2022
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy
NCT07594015RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Miami, United States
Started: Aug 6, 2026
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
NCT07368985NOT YET RECRUITINGPHASE2
87 participants
INTERVENTIONAL
Rotterdam, Netherlands
Started: Mar 1, 2026
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453RECRUITINGPHASE1, PHASE2
317 participants
INTERVENTIONAL
New York, United States +12 more
Started: Aug 2, 2021
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04781088ACTIVE NOT RECRUITINGPHASE2
38 participants
INTERVENTIONAL
Columbus, United States +1 more
Started: Sep 1, 2021
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT06253494RECRUITINGPHASE1, PHASE2
60 participants
INTERVENTIONAL
Bethesda, United States
Started: May 14, 2024
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT05603910RECRUITINGPHASE1
18 participants
INTERVENTIONAL
Miami, United States
Started: Apr 15, 2023
Completed Clinical Trials
8 completed trials for Lenvatinib + Pembrolizumab in Uterine Cancer
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
NCT03006887COMPLETEDPHASE1
6 participants
INTERVENTIONAL
Chuo-ku, Japan
Started: Jan 12, 2017
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
NCT04865289COMPLETEDPHASE3
130 participants
INTERVENTIONAL
Hefei, China +21 more
Started: Oct 22, 2019
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
NCT03884101COMPLETEDPHASE3
842 participants
INTERVENTIONAL
Mobile, United States +194 more
Started: Apr 11, 2019
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT06036836COMPLETEDPHASE2
163 participants
INTERVENTIONAL
New Haven, United States +43 more
Started: Sep 29, 2023
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449COMPLETEDPHASE3
827 participants
INTERVENTIONAL
Phoenix, United States +168 more
Started: Jun 11, 2018
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT05007106COMPLETEDPHASE2
613 participants
INTERVENTIONAL
Anchorage, United States +72 more
Started: Sep 16, 2021
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
NCT05375136COMPLETED
135 participants
OBSERVATIONAL
Bundang, South Korea +18 more
Started: Jun 25, 2021
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study
NCT06599463COMPLETED
351 participants
OBSERVATIONAL
Angers, France +23 more
Started: Aug 19, 2024